Evaxion — AI-designed personalized neoantigen vaccines (EVX-01) on its PIONEER prediction platform.
Danish clinical-stage techbio Evaxion (Nasdaq: EVAX) has announced new three-year immune and clinical outcome data for personalized cancer vaccine EVX-01 in patients with advanced melanoma, with the news sending the firm’s share up almost 9% to $3.71 in pre-market trading. The da…
Evaxion (Nasdaq: EVAX) reported three-year follow-up from its Phase II trial of personalized cancer vaccine EVX-01 in advanced melanoma: all patients maintained the clinical responses observed at two years, with no tumor progression, and received EVX-01 as stand-alone therapy in the third year. Shares rose 5.5% to $2.99 in pre-market trading on the news. For a techbio whose vaccines come off its AI-Immunology platform, extended response durability without progression is the key evidence point that its AI-selected antigens translate into lasting clinical benefit, and stand-alone activity in year three strengthens the case beyond earlier-trial contexts.
Evaxion (EVAX) reported two-year phase 2 data for its personalized neoantigen vaccine EVX-01 plus pembrolizumab in advanced melanoma: 12 of 16 patients responded, and 86% of EVX-01 neoantigen targets triggered a tumor-specific immune response. New analyses looking beyond vaccine-specific T-cell responses at effects across the immune system will be presented orally and as posters at SITC 2026 in November. Durable follow-up paired with mechanistic depth is the data package a clinical-stage vaccine developer needs for partnership conversations and next-trial design.
Evaxion will present three-year clinical efficacy data for its personalized cancer vaccine, EVX-01, at the ESMO Congress 2026. The presentation focuses on long-term outcomes, offering investors insight into the durability of patient responses to this neoantigen-targeted therapy.
17.7.2026 13:15:00 CEST | GlobeNewswire by notified | Press release COPENHAGEN, Denmark, July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, will present three-year clinica…
The data stems from a one-year extension of the phase 2 trial evaluating EVX-01 in patients with advanced melanoma (skin cancer). In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not admini…
Datavault AI Announces Tokenization of Available Infrastructure’s... Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results ... Hyperscale Data Begins Installation of Omnipresent Robotics OPR-R... Faraday Future Showcases Its EAI Robot World Across Three High-Le... Lian…